NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Home/Weight Loss & Metabolic/Mazdutide

Mazdutide

Dual GLP-1/glucagon receptor agonist peptide in clinical development for obesity and type 2 diabetes.

Overview

Mazdutide is an investigational synthetic peptide that acts as an agonist at both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is being developed primarily in China by Innovent Biologics, with chemistry licensed from Eli Lilly, as a once-weekly treatment for type 2 diabetes and obesity. Published phase 2 results in Chinese adults with overweight, obesity, or type 2 diabetes reported dose-dependent weight loss and glycemic improvements.

Mechanism

Dual agonism is designed to combine the appetite-suppressing and insulinotropic effects of GLP-1 with the energy-expenditure and lipolytic effects of glucagon receptor signaling. The balance of the two activities is intended to produce greater weight loss than GLP-1 agonism alone while minimizing glucagon-driven hyperglycemia.

Dosing

In clinical trials mazdutide is administered as a once-weekly subcutaneous injection at dose levels defined by each study protocol. It is an investigational drug; dosing outside registered trials is not appropriate.

Expected Effects

  • dose-dependent body-weight reduction in phase 2 trials in adults with overweight or obesity
  • reductions in HbA1c in trials enrolling people with type 2 diabetes
  • improvements in some cardiometabolic markers in early studies

Side Effects & Tolerability

Reported adverse events are typical of the incretin class, principally gastrointestinal (nausea, vomiting, diarrhea), with severity increasing at higher doses. Long-term safety data from larger phase 3 programs are still being generated.

Storage

Investigational drug supplies are handled per the trial sponsor's instructions; no consumer storage guidance applies to an unapproved medicine.

Related peptides

AdipotideInvestigational prohibitin-targeting pro-apoptotic peptide conjugate studied in obese mice and monkeys to reduce adipose vasculature; not tested in humans.Advanced Thermogenic Master AnalogsMarketing-style catalog label implying peptides that enhance thermogenesis; no defined compound exists under this name in the literature.AMPK & mTOR Balance AnalogsCatalog label implying peptides that modulate the AMPK/mTOR signaling balance; no specific compounds are characterized under this name.Amylin Analogs (Expanded)Class listing for synthetic analogs of the pancreatic hormone amylin; pramlintide is the approved reference agent, while novel long-acting analogs are investigational.Autophagy Enhancer Peptide AnalogsCatalog category for peptides claimed to enhance autophagy; not a recognized compound class in the literature.C-Peptide AnalogsSynthetic peptides related to the proinsulin connecting peptide, whose native form has been studied as an adjunct in type 1 diabetes; analogs are undocumented.